SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 13 of 23
Word Count: 1500
Character Count: 9891

Document Content:

months ended September 30, 2024, 12% of our net revenue in the year ended December 31, 2024, compared to 13% for the year ended December 31, 2023. Competition The U.S. nutritional supplements retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other domestic and international manufacturers, specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies, and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. Certain of our competitors may have significantly greater financial, technical and marketing resources than we do, and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing new products. Corporate Information

We were organized as a corporation
under the laws of the State of Nevada on December 29, 2010 under the name “Oro Capital Corporation.” In April 2014,
Synergy Strips Corp., a Delaware corporation, became our wholly-owned subsidiary, and we changed our name from “Oro Capital
Corporation” to “Synergy Strips Corp.” In August 2015, we changed our name to “Synergy CHC Corp.” In
January 2019, our other U.S. subsidiaries, Neuragen Corp., Sneaky Vaunt Corp., The Queen Pegasus Corp. and Breakthrough Products
Inc., merged with and into the Company. Synergy is the sole owner of four subsidiaries: NomadChoice Pty Ltd., Hand MD Corp., Synergy CHC
Inc. and Synergy CHC Mexico, and the results have been consolidated in these statements. Synergy CHC Mexico was incorporated during May
2025 for the purposes of expanding into Mexico.

We completed our initial public
offering on October 24, 2024, and became subject to the information and reporting requirements of the Exchange Act. We file
periodic reports, proxy statements and other information with the SEC.

The address of our principal
executive offices is 865 Spring Street, Westbrook, Maine 04092 and our phone number is (207) 321-2350. Our website is www.synergychc.com.
The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this
prospectus.

RISK FACTORS

Investing in our securities
involves significant risks. Before making an investment decision, you should carefully consider the risks and other information we include
or incorporate by reference in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under
the heading “Risk Factors” included in our most recent Annual Report on Form 10-K, as may be revised or supplemented by our
subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, each of which are on file with the SEC and are incorporated
herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the
future. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not
currently known to us may also affect our business operations. Additional risk factors may be included in a prospectus supplement relating
to a particular offering of securities. Our business, financial condition or results of operations could be materially adversely affected
by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your
investment. This prospectus is qualified in its entirety by these risk factors.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus, including
the documents that we incorporate by reference, contains forward-looking statements as that term is defined in the federal securities
laws. The events described in forward-looking statements contained in this prospectus, including the documents that we incorporate by
reference, may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or
other consequences of our plans or strategies, financing plans, projected or anticipated benefits from acquisitions that we may make,
or projections involving anticipated revenues, earnings or other aspects of our operating results or financial position, and the outcome
of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management.
We intend for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such
as “may,” “expect,” “believe,” “anticipate,” “project,” “plan,”
“intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to
identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are
subject to a number of uncertainties, risks and other influences, many of which are beyond our control that may influence the accuracy
of the statements and the projections upon which the statements are based. Factors that may affect our results include, but are not limited
to, the risks and uncertainties discussed in any prospectus supplement to this prospectus in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2024 or in other reports we file with the SEC, among other things:

●	our ability to compete in our industry, including against competitors
that have significantly greater financial, technical and marketing resources than we do;

●	our ability to respond to customer preferences and successfully
develop new and innovative products in a timely manner and effectively manage the introduction of new or enhanced products;

●	risks related to a loss of, or material cancellation, reduction,
or delay in purchases by, one or more of our largest customers;

●	our outside suppliers and manufacturers failing to supply products
in sufficient quantities and in a timely fashion;

●	our ability to execute on our strategic initiatives (including
acquisitions);

●	our ability to maintain the reputation of our brands;

●	the risks related to consumers’ perception of the safety
and quality of our products as well as similar products distributed by other companies in our industry;

●	the risks related to third parties asserting intellectual property
infringement claims against us;

●	the risks related to our planned expansion into additional international
markets;

●	the risks related to adverse economic conditions;

●	the risks related to catastrophic events;

●	our ability to retain key personnel, manage our business effectively,
and continue to grow;

●	the impact of numerous laws and regulations that apply to the
manufacture, sale, and manufacturing of nutritional supplements, and compliance with these laws and regulations, as they currently exist
or as modified in the future, on us and our suppliers;

●	the risks related to product recalls; and

●	the risks related to product liability claims and litigation
to prosecute such claims;

Any one or more of these uncertainties,
risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately
prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these
forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information,
future events or otherwise.

You should rely only on the
information in this prospectus and any related prospectus supplement. We have not authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information, you should not rely upon it.

USE OF PROCEEDS

Unless we inform you otherwise
in the prospectus supplement relating to a particular offering of securities, we will use the net proceeds from the sale of the securities
offered by this prospectus and the exercise price from the exercise of any convertible securities, if any, for research and development
expenses, working capital and other general corporate purposes, which may include funding acquisitions or investments in businesses, products
or technologies that are complementary to our own and reducing indebtedness.

When particular securities
are offered, the prospectus supplement relating to that offering will set forth our intended use of the net proceeds received from the
sale of those securities we sell. Pending the application of the net proceeds for these purposes, we expect to invest the proceeds in
short-term, interest-bearing instruments or other investment-grade securities.

THE SECURITIES WE MAY OFFER

General

The descriptions of the securities
contained in this prospectus, together with the applicable prospectus supplements, summarize all of the material terms and provisions
of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities
the particular terms of the securities offered by that prospectus supplement. If we indicate in the applicable prospectus supplement,
the terms of the securities may differ from the terms we have summarized below. We may also include in the prospectus supplement information
about material United States federal income tax considerations relating to the securities, and the securities exchange, if any, on which
the securities will be listed.

We may sell from
time to time, in one or more offerings:

●	common stock;

●	preferred stock;

●	warrants to purchase shares of our common stock or preferred stock;